Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Fulvestrant gives prolonged response in women with advanced breast cancer
July 4th, 2002
Encouraging data presented at the American Society of Clinical Oncology (ASCO) have shown that Faslodex is at least as effective as Arimidex in the treatment of hormone receptor positive postmenopausal women with advanced breast cancer. It also provides a longer mean duration of response in this setting. This promising finding adds to a growing body of evidence to support Faslodex use in the advanced setting, suggesting it is a valuable additional endocrine treatment option for these patients. Previous data analysis has already shown that the use of Faslodex following antiestrogen therapy for advanced disease does not compromise the potential for efficacy of...
Source: Women's Health Weekly (2002-07-04)
|
